Oppenheimer analyst Jay Olson maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) yesterday and set a price target of $97.00. The company’s shares closed last Monday at $52.01, close to its 52-week low of $50.01.
According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.6% and a 32.9% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Enanta Pharmaceuticals, and Axovant Gene Therapies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAGE Therapeutics with a $94.13 average price target, implying a 73.7% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $125.00 price target.
The company has a one-year high of $193.56 and a one-year low of $50.01. Currently, SAGE Therapeutics has an average volume of 1.22M.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SAGE in relation to earlier this year. Most recently, in December 2019, Albert Robichaud, the CSO of SAGE bought 15,743 shares for a total of $316,746.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.